Mesenchymal hamartoma of the chest wall in infants: Report of three cases and literature review

Mesenchymal hamartoma of the chest wall in infants is a rare abnormality. We present a report of three cases and a brief review of the literature, emphasizing the role of the radiologist in diagnosis and management.     

MRI预测急性脑梗死后出血的价值

目的探讨急性脑梗死患者MR早期增强T1WI中脑实质强化及大脑中动脉高信号（HMCA）征与继发性脑出血（HT）的关系。方法回顾性分析24例发病6．0h内[平均（4．3±1．4）h]的急性脑梗死患者首次T1WI及随后1周内复查的MRI和（或）CT资料，了解首次增强T1WI脑实质强化和HMCA征与HT的关系。早期脑实质强化为脑梗死6．0h内缺血的脑组织区域在增强T1WI出现高信号；HMCA征为增强T1WI上大脑中动脉增粗（与对侧相比）、出现边缘模糊的高信号。结果24例患者中10例发展为HT（出血组），其中6例首次T1WI可见脑实质强化，5例出现HMCA征；14例未出现HT（无出血组），均未发现脑实质强化和（或）HMCA征。2组相比，T1WI脑实质强化、HMCA征出现率差异均有统计学意义（P值均〈0．01）。结论T1WI早期脑实质强化和HMCA征有可能预测急性脑梗死后HT。     

Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis

Background Cyclosporin A (CsA) is being increasingly used in the treatment of severe refractory atopic dermatitis. Clinical efficacy and safety of short‐term cyclosporin A treatment in atopic dermatitis patients has been proven, however, data on long‐term treatment are limited. Objective The aim of this study was to investigate the efficacy, safety and the effect of discontinuation of cyclosporin A treatment in atopic dermatitis patients, with a particular focus on patients treated with cyclosporin A for more than 6 months. Methods We performed a retrospective study of clinical and adverse effects of cyclosporin A treatment in 73 atopic dermatitis patients, with an average duration of cyclosporin A treatment of 1.3 years. Results We included 73 patients (31 women and 42 men, with a mean age of 33.8 years) with severe atopic dermatitis refractory to conventional therapy that was treated with cyclosporin A. Treatment was successful in 56/73 patients. Increases in serum creatinine levels > 30% compared to baseline were reported in 7/73 patients. Arterial hypertension appeared in 11/73 patients during treatment. After discontinuation of treatment, 40/73 patients experienced a relapse and 33/73 patients experienced clinical remission for at least 3 months. No correlation between treatment duration and nephrotoxicity or hypertension was found. Strikingly, 6/73 patients experienced a rebound phenomenon. Conclusions We conclude that CsA is an effective and safe treatment for patients with severe AD refractory to conventional treatment, provided that the recommended guidelines for its administration are strictly observed. However, in contrast to previous reports, we found that 8% (6/73) of patients experienced a rebound phenomenon after discontinuation of treatment.     

自体骨软骨镶嵌移植术修复关节软骨缺损

目的：回顾性分析关节镜下自体骨软骨镶嵌式移植术治疗负重面关节软骨损伤的可行性。方法：采用Smith Nephew镶嵌式骨软骨移植器，在关节镜下挖取膝关节非负重关节面骨软骨条，并将之移检修复膝关节负重面的局灶性软骨缺损。结果：手术15例，术后随访7—12个月，平均9个月，均达到优良效果。结论：自体关节骨软骨镶嵌移植术对关节负重面局灶性软骨缺损有较好、确实的治疗效果。     

O9 Creation of oral care flavours to deliver breath freshening benefits – an in vitro method

Flavours conventionally help to deliver breath freshening in oral care products via sensory masking. The aim of this study was to determine whether flavours could additionally inhibit formation of malodorous compounds by bacteria. Oral malodour is in large part related to the production of volatile sulphur compounds (VSCs) by Gram-negative organisms. We therefore developed a quantitative in vitro assay for hydrogen sulphide production by Klebsiella pneumoniae . The entire Quest dental flavour palette was screened for inhibition of H₂S production. A database of flavour ingredient effects was created, and used to create VSC-inhibitory flavours. These flavours were assessed in the in vitro assay to confirm that the compounded flavour performed as expected. The best performing flavours developed in this way were selected for testing in the Quest Breath Freshness Panel (see poster, P21). Rules based on the performance of dental flavour ingredients, singly or in combination, were also used to develop a patent position. Flavours formulated using these rules (termed Q-fresh flavours) have been incorporated into a range of oral care products including toothpastes, mouthwashes, chewing gums and breath films. These products have been tested in the Quest Breath freshness panel, and have been shown to deliver significant breath freshening benefits. An in vitro VSC-inhibition method has allowed reliable development of flavours with breath-freshening benefits.